Rhythm Pharmaceuticals RM-718 shows BMI reduction in Phase 2 trial

August 4, 2026 6:55 AM

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) reported preliminary data from an ongoing Phase 2 trial evaluating RM-718, an investigational once-weekly MC4R ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found